טוען...
Practical management of patients with myelofibrosis receiving ruxolitinib
Myelofibrosis (MF) is characterized by bone marrow fibrosis, progressive anemia and extramedullary hematopoiesis, primarily manifested as splenomegaly. Patients also experience debilitating constitutional symptoms, including sequelae of splenomegaly, night sweats and fatigue. Ruxolitinib (INC424, IN...
שמור ב:
| הוצא לאור ב: | Expert Rev Hematol |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2013
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8201600/ https://ncbi.nlm.nih.gov/pubmed/24083419 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/17474086.2013.827413 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|